Utilising the impact of COVID-19 on trauma throughput to adapt elective care models for more efficient trauma care

Table 3 Patient demographics, length of stay, comorbidity indices and theatre parameters for 2018

	Phase 0 (n = 709)	Phase 1 (n = 571)	Phase 2 (n = 1363)	Phase 3 (n = 486)	Total (n = 3129)
	mean ± SD
Age at injury	61.23 ± 22.40	56.40 ± 24.04	57.52 ± 24.36	59.06 ± 23.79	58.39 ± 23.83
Length of spell (d)	8.39 ± 10.31	6.84 ± 8.57	6.76 ± 10.19	7.02 ± 9.45	7.18 ± 9.84
Charlson Comorbidity Index	0.72 ± 1.31	0.65 ± 1.24	0.68 ± 1.26	0.60 ± 1.21	0.67 ± 1.26
Elixhauser Comorbidity Index	1.19 ± 1.39	1.09 ± 1.36	1.14 ± 1.38	1.06 ± 1.31	1.13 ± 1.37
Hours to surgery	29.24 ± 50.75	31.46 ± 48.29	34.72 ± 91.27	26.22 ± 52.95	31.54 ± 71.10
Time in theatre	98.59 ± 58.34	92.86 ± 48.23	94.33 ± 46.30	95.49 ± 48.66	95.23 ± 50.04
Time in theatre/recovery	61.23 ± 22.40	56.40 ± 24.04	57.52 ± 24.36	59.06 ± 23.79	58.39 ± 23.83
Sex: Female	383 ± 54.0%	296 ± 51.8%	726 ± 53.3%	249 ± 51.2%	1654 ± 52.9%
Sex: Male	326 ± 46.0%	275 ± 48.2%	637 ± 46.7%	237 ± 48.8%	1475 ± 47.1%